VIRX - Day One wins FDA nod brain cancer therapy Ojemda
2024-04-23 13:59:37 ET
More on Day One Biopharma, Viracta, etc.
- Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
- Viracta slides on lower response rate in trial for lymphoma treatment cohort
- Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share
- Seeking Alpha’s Quant Rating on Day One Biopharmaceuticals
- Historical earnings data for Day One Biopharmaceuticals